Cashing in on dementia patients: drugmaker to pay $116 million in fraud settlement

A pharmaceutical company that whistleblowers alleged paid doctors to prescribe its main drug and urged salespeople to push it as a way to control unruly dementia patients will pay more than $100 million to settle government fraud allegations.